Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. - Wikidata - wikimedia - TriplyDB

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.

http://www.wikidata.org/entity/Q36921518

about

Concepts and clinical use of ultra-long basal insulin Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden Utility scores for vesicoureteral reflux and anti-reflux surgery.Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes Approach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources Self-rated quality of life of city-dwelling elderly people benefitting from social help: results of a cross-sectional study.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.The patient perspective of diabetes care: a systematic review of stated preference research.Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia.Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.Incidence and cost of hypoglycemic events requiring medical assistance in a hospital setting in Denmark.History of mild hypoglycaemia does not affect the prevalence of diabetes-related distress in people with diabetes.Individual and societal consequences of hypoglycemia: A cross-sectional survey.Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries.Incidence of non-severe hypoglycaemia and intensity of treatment among veterans with type 2 diabetes in the U.S.A.: a prospective observational study.Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic.Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.

P2860

Q26770354-84CE836B-7DA8-4B64-83F6-5EADB39AD32B Q26784381-2BEFEF19-0B7B-4EF9-9C98-860B6427AB0A Q28069299-F33C665B-A055-42BB-8BBC-1FCC218F8A77 Q28554260-FC060EFA-B640-4AAF-822F-AC49FB8BBC4C Q31152059-D2443CF4-E4C3-48C9-9C82-7917868CBB19 Q33732593-601D3C92-5D81-44F1-8979-B2BD145A4BE6 Q34726534-6A5D4AB9-2EF7-45E3-9B74-1A321BCAD193 Q35967501-DCBB4763-F0FC-4726-8FF7-72E82245A1FE Q36860522-CA7159D3-8677-40C2-AD7D-872E5443FF0A Q37269489-91CB6264-9ADA-4F5F-8800-3C0F450BDC95 Q37279137-D361CE9E-F347-4CF1-932F-3307C6E2FBF4 Q37284658-94F7BDE7-E1CA-4CC0-9465-8E9E9547D9DB Q37639302-6C7511A8-EB63-4B81-ACB4-F8FBBB67EB41 Q37689556-6A586E43-5CBD-4000-AEA4-14D87E6D8B7D Q37737461-C8653C8F-C040-4A6D-8A59-961E1759C190 Q38201315-DDB8D93D-C4DE-44EC-B263-A80B7EB8B392 Q38241834-50FA92FA-E5DC-49DA-A895-0937AB6EDADE Q38470334-B839F7F3-E84E-4D3D-94AD-74A7AC1CE50B Q38675810-66D4C7C5-D480-4594-BD1D-1FBB68801B51 Q38738725-04D5D72D-B9A2-4BA2-832E-02C804B9EDFB Q38775589-3EC60152-D823-4B04-9CF3-F54453841DC3 Q38907289-DB53565C-9BEE-4284-B82F-3E79E1B499DF Q39321463-AD8ED9AE-BC5E-4CA5-AB2B-97B891AD8678 Q39340832-4E2D8FC2-7D13-459E-8CF8-858273D701D7 Q39462093-C1C143EA-8782-4D20-8602-D936E1EB96DC Q39667350-C118D4F8-6686-48D8-88D8-F46B602342FF Q39791634-9FE84D2F-8B2D-40C9-AF3A-8499DE011347 Q39842123-F8C56688-9664-4C2B-8D73-D7F9F7B500BE Q40649008-4BC0E62E-AC44-42CC-BD28-722753E96683 Q41740597-A4838D8B-AA12-4FE5-842E-F0C748EFF96D Q42213808-9B3C4E5B-3D3E-463D-B3BA-9F5D0827CBAF Q44046095-5A7B3100-2CED-4521-80A9-1CB9C839A9FE Q44781339-72583EF7-12DD-46E2-8417-A39C6878B800 Q47117737-89CDD8C9-660A-4E0A-A5C5-6218081AD3A9 Q47136443-7E62A6AE-0C15-4726-88AD-EDF26A1944CD Q47557627-BF536D64-8CA5-48C8-84BC-CC24FD969185 Q48097169-32BBBE6F-36DE-4443-ABA9-411A1AAE0AD1 Q50145776-6EFD6348-2618-4C02-BE24-A3B0D75B6FBD Q51241132-942204DE-BE79-4D04-B3BD-B21C58308EF2 Q54959259-2C3CBB28-A846-4B7A-A261-1228902F5095

P2860

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.

http://www.wikidata.org/entity/Q36921518

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Health-related quality of life ...... -off survey in five countries.

@en

type

label

Health-related quality of life ...... -off survey in five countries.

@en

prefLabel

Health-related quality of life ...... -off survey in five countries.

@en

P1433

Q36921518-42494F82-22D6-4A4B-8534-6B7E8B286A0B

P1476

Q36921518-7E99E63B-B096-4C3F-B184-90D1F155E400

P2093

Q36921518-01DCADA1-0541-42DB-9C2F-4E1D3D601CE4

Q36921518-0FFD63A3-880A-4D56-B011-B69929FBE957

Q36921518-4FF424D0-8D71-4408-9BDA-E16D1D35AE4C

Q36921518-6D4DA75F-F41F-4529-9316-A711721AA4DF

Q36921518-77E60B09-5A83-4853-AE81-250A60097F17

Q36921518-CF150EDA-E937-4378-BD2A-7EB452B3EA5A

P2860

Q36921518-02A0503B-44D1-4B45-829D-5902F6F02C01

Q36921518-05548280-8A4A-4FCD-AA2E-39BA1D25DC16

Q36921518-0D363000-68B9-4FA6-80A3-99F510E6919A

Q36921518-1809DAD3-5A3F-45ED-A39E-35891ADF6794

Q36921518-221E0A23-9047-4771-8644-DEDF4129B5B3

Q36921518-330E228C-8987-4DC0-BED3-FBE388F9A22C

Q36921518-34FFA5DD-1F63-45B9-BAEC-80B5383E30C1

Q36921518-38E77D20-D872-4976-9470-6EC3D82455C6

Q36921518-3D3992A3-EC89-4629-B99B-48816D68BD21

Q36921518-4EDFC78A-4C43-490F-8516-A012AA72FF46

P2888

Q36921518-1D4B75D4-FF89-4D47-8B72-CB27910936CC

P304

Q36921518-49396237-3FB7-4EE9-B84A-804AC63D6E3E

P31

Q36921518-4540908A-9BAA-44A7-9279-34293008292F

P356

Q36921518-EA8F1F89-8DE6-4333-9BD6-E0A5EE0EC52E

P478

Q36921518-3D50CB2C-5C9E-4157-8BAC-A16C623F5F94

P50

Q36921518-A7DFC646-F4A2-42AF-8677-0D5E61915525

P577

Q36921518-78B8765F-8CC7-4619-8D04-C985EC9B5903

P5875

Q36921518-9DE88176-905D-4402-B2D0-FD964241AD0D

P6179

Q36921518-C00FB0E7-DB17-4111-B490-F513D8C70FB6

P698

Q36921518-BB71FA8B-CFB6-4485-BB74-E488D63B12FF

P932

Q36921518-D8A28E57-1FF6-45EF-B43A-0CB757F13A58

P356

1477-7525-11-90

P1433

Health and Quality of Life Outcomes

P1476

Health-related quality of life ...... -off survey in five countries.

@en

P2093

Claus B Galbo-Jørgensen

http://www.w3.org/2001/XMLSchema#string

Jens Gundgaard

http://www.w3.org/2001/XMLSchema#string

Marc Evans

http://www.w3.org/2001/XMLSchema#string

Mette Bøgelund

http://www.w3.org/2001/XMLSchema#string

Muhammad Mamdani

http://www.w3.org/2001/XMLSchema#string

Stewart Harris

http://www.w3.org/2001/XMLSchema#string

P2860

What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D

Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.

Impaired awareness of hypoglycaemia: a review.

Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study

Introducing economic and quality of life measurements into clinical studies.

Measurement of health status. Ascertaining the minimal clinically important difference.

Responsiveness and minimal important differences for patient reported outcomes.

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.

Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom.

P2888

1477-7525-11-90

P304

90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1477-7525-11-90

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237016031

http://www.w3.org/2001/XMLSchema#string

P6179

1013049175

http://www.w3.org/2001/XMLSchema#string

P698

23731777

http://www.w3.org/2001/XMLSchema#string

P932

3679729

http://www.w3.org/2001/XMLSchema#string